SQLite Web: event_store.db

Update row sig_c0f3822b02f6 in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000036.txt","as_of":"2026-04-22T03:03:32.063787+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000036.txt","company":"UNITED THERAPEUTICS Corp","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000036.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_00e6cacc5fb00271","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000036.txt","content_type":"text/plain","enriched_at":"2026-04-22T03:12:52.472983+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000036.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000036.txt","source_event_id":"evt_146dd1f17d49","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"a05bd9d8b02e9079","kind":"sec_filing","published_at":"20260421","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-21","2026-04-20","2025-11-07","2027-03-17","2026-12-31"],"entities":[{"asset_class":"equity","name":"UNITED THERAPEUTICS Corp","relevance":"high","symbol":"UTHR","type":"issuer"},{"asset_class":"equity","name":"ROTHBLATT MARTINE A","relevance":"high","symbol":"","type":"reporting_person"},{"asset_class":"other","name":"Martine A. Rothblatt 10b5-1 trading plan","relevance":"medium","symbol":"","type":"trading_plan"}],"event_type":"listing","information_gaps":["The cleaned text does not clearly enumerate the exact number of options exercised and/or exact number of shares sold in each line item; it shows multiple \u201cCommon Stock\u201d and \u201cStock Option\u201d entries but the mapping to specific quantities is not fully unambiguous from the provided excerpt.","The signal does not include a prior known state, so the \u201cwhat changed vs prior\u201d delta cannot be determined from the provided text alone.","The filing excerpt is truncated mid-sentence near the end (\u201cThis transaction was executed in multiple trades at prices ranging from $576.48 to $577.40\u2026\u201d then repeats and cuts off), so additional details may be missing."],"key_facts":["SEC filing is Form 4 for UNITED THERAPEUTICS Corp (issuer CIK 0001082554).","Filing was filed as of 2026-04-21 and covers the reporting period/conformed period of report 2026-04-20.","Reporting owner is Martine A. Rothblatt (Chairperson & CEO) with reporting owner CIK 0001106578.","The filing states the transactions were pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.","The plan is stated to continue until the earlier of: (a) exercise of 1,734,410 stock options (all expiring March 17, 2027) or (b) December 31, 2026.","The filing states the transaction was executed in multiple trades at prices ranging from $571.90 to $572.88 (weighted average price reported above).","The filing includes additional repeated statements of multiple trade price ranges (e.g., $573.035 to $573.98; $574.47 to $575.41; $575.48 to $576.47; $576.48 to $577.40; $577.48 to $578.42), each with weighted average price language."],"numeric_claims":[{"label":"Options exercised (stated plan total)","value":"1,734,410"},{"label":"Option expiration (stated plan)","value":"2027-03-17"},{"label":"Plan end date (stated plan)","value":"2026-12-31"},{"label":"10b5-1 plan adoption date","value":"2025-11-07"},{"label":"Transaction execution date (conformed period of report)","value":"2026-04-20"},{"label":"Trade price range (one stated range)","value":"$571.90 to $572.88"},{"label":"Trade price range (another stated range)","value":"$573.035 to $573.98"},{"label":"Trade price range (another stated range)","value":"$574.47 to $575.41"},{"label":"Trade price range (another stated range)","value":"$575.48 to $576.47"},{"label":"Trade price range (another stated range)","value":"$576.48 to $577.40"},{"label":"Trade price range (another stated range)","value":"$577.48 to $578.42"}],"primary_claim":"On 2026-04-20, Martine A. Rothblatt executed stock option exercises and sold resulting United Therapeutics common shares under a 10b5-1 trading plan adopted November 7, 2025, as reported in a Form 4 filed April 21, 2026.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"United Therapeutics (UTHR) disclosed on Form 4 filed 2026-04-21 that reporting person Martine A. Rothblatt executed option exercises and sales of resulting common shares on 2026-04-20. The transactions were conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-11-07.","topics":["SEC Form 4","insider trading","10b5-1 plan","stock option exercise","sale of common stock"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 UNITED THERAPEUTICS Corp \u00b7 Filed 20260421","ticker":"UTHR","tickers":["UTHR"],"title":"UTHR filed 4","url":"https://www.sec.gov/Archives/edgar/data/1082554/0001106578-26-000036.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel